{"id":543918,"date":"2021-05-19T23:22:01","date_gmt":"2021-05-19T23:22:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=543918"},"modified":"2021-05-19T23:22:01","modified_gmt":"2021-05-19T23:22:01","slug":"multiple-system-atrophy-msa-market-analysis-market-size-epidemiology-leading-companies-and-therapies-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/multiple-system-atrophy-msa-market-analysis-market-size-epidemiology-leading-companies-and-therapies-delveinsight_543918.html","title":{"rendered":"Multiple System Atrophy (MSA) Market Analysis, Market Size, Epidemiology, Leading Companies And Therapies | DelveInsight"},"content":{"rendered":"
\"Multiple<\/a><\/p>\n
\n
Delveisight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u2018Multiple System Atrophy (MSA)-Market Insights, Epidemiology, and Market Forecast\u20132030\u2019 report deliver an in-depth understanding of the MSA, historical and forecasted epidemiology as well as the MSA market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.<\/p>\n<\/div>\n

DelveInsight has launched a new report on “Multiple System Atrophy (MSA) – Market Insights, Epidemiology, and Market Forecast-2030<\/strong>”.<\/p>\n

DelveInsight’s<\/span> “Multiple System Atrophy (MSA) – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a><\/span>” report delivers an in-depth understanding of the Multiple System Atrophy (MSA), historical and forecasted epidemiology as well as the  Multiple System Atrophy (MSA) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/span><\/p>\n

Some of the key facts of the Report:<\/span><\/strong><\/p>\n

    \n
  1. \n

    MSA is the most frequent disorder among atypical Parkinsonism with an estimated prevalence of 2–5 per 100,000 inhabitants<\/span>.<\/span>This feature may have been overestimated because these series are well known to be biased toward atypical Parkinsonism cases<\/span>.<\/span><\/p>\n<\/li>\n

  2. \n

    The prevalence in the USA is reported to be between 3 and 4 cases per 100,000 patients per year for people aged 50–99 years <\/span><\/p>\n<\/li>\n

  3. \n

    The standardized prevalence rates indicate 4–5 cases per 100,000 persons. In the age group >55 years, 17–29 cases per 100,000 persons have been observed.  In Italy, 4,900 prevalent cases have been estimated based on  study .<\/span><\/p>\n<\/li>\n<\/ol>\n

    Key benefits of the report:<\/span><\/strong><\/p>\n

    1. Multiple System Atrophy (MSA) market report covers a descriptive overview and comprehensive insight of the Multiple System Atrophy (MSA) epidemiology and Multiple System Atrophy (MSA) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/span><\/p>\n

    2. The Multiple System Atrophy (MSA) market report provides insights on the current and emerging therapies.<\/span><\/p>\n

    3. Multiple System Atrophy (MSA) market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/span><\/p>\n

    4. The Multiple System Atrophy (MSA) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Multiple System Atrophy (MSA) market.<\/span><\/p>\n

    Request for sample pages<\/span>: https:\/\/www.delveinsight.com\/sample-request\/multiple-system-atrophy-msa-market<\/span><\/a><\/span>
    <\/span><\/a><\/strong><\/p>\n

    Multiple System Atrophy (MSA): Overview<\/span><\/strong><\/p>\n

    Multiple System Atrophy<\/span> (<\/span>MSA<\/span>) is a rare neurodegenerative disorder that can cause a multitude of symptoms in any combination including impairments to balance, difficulty with movement, poor coordination, bladder dysfunction, sleep disturbances and poor blood pressure control.<\/span><\/p>\n

    The key players involved in the Multiple System Atrophy (MSA) market<\/a>:<\/span><\/strong><\/p>\n

      \n
    1. \n

      Theravance Biopharma<\/span><\/p>\n<\/li>\n

    2. \n

      Biohaven Pharmaceutical <\/span><\/p>\n<\/li>\n

    3. \n

      ProMIS Neurosciences<\/span><\/p>\n<\/li>\n<\/ol>\n

      The launch of the emerging therapies is expected to significantly impact the  Multiple System Atrophy (MSA) treatment scenario in the upcoming years:-<\/span><\/strong><\/p>\n

      Drug covered<\/span><\/strong><\/p>\n

        \n
      1. \n

        TD-9855<\/span><\/p>\n<\/li>\n

      2. \n

        BHV-3241<\/span><\/p>\n<\/li>\n

      3. \n

        Alpha synuclein<\/span><\/p>\n<\/li>\n<\/ol>\n

        Request a free sample report @https:\/\/www.delveinsight.com\/sample-request\/multiple-system-atrophy-msa-market<\/span><\/a><\/span><\/strong><\/p>\n

        Table of Contents<\/span><\/strong><\/p>\n

        1. Report Introduction<\/span><\/p>\n

        2. Executive Summary<\/span><\/p>\n

        3. SWOT analysis<\/span><\/p>\n

        4. Multiple System Atrophy (MSA) Patient Share (%) Overview at a Glance<\/span><\/p>\n

        5. Multiple System Atrophy (MSA) Market Overview at a Glance<\/span><\/p>\n

        6. Multiple System Atrophy (MSA) Disease Background and Overview<\/span><\/p>\n

        7. Multiple System Atrophy (MSA) Epidemiology and Patient Population<\/span><\/p>\n

        8. Country-Specific Patient Population of Multiple System Atrophy (MSA)<\/span><\/p>\n

        9. Multiple System Atrophy (MSA) Current Treatment and Medical Practices<\/span><\/p>\n

        10. Unmet Needs<\/span><\/p>\n

        11. Multiple System Atrophy (MSA) Emerging Therapies<\/span><\/p>\n

        12. Multiple System Atrophy (MSA) Market Outlook<\/span><\/p>\n

        13. Country-Wise Multiple System Atrophy (MSA) Market Analysis (2017–2030)<\/span><\/p>\n

        14. Market Access and Reimbursement of Therapies<\/span><\/p>\n

        15. Market drivers<\/span><\/p>\n

        16. Market barriers<\/span><\/p>\n

        17. Appendix<\/span><\/p>\n

        18. Multiple System Atrophy (MSA) Report Methodology<\/span><\/p>\n

        19. DelveInsight Capabilities<\/span><\/p>\n

        20. Disclaimer<\/span><\/p>\n

        21. About DelveInsight<\/span><\/p>\n

        Related Reports:<\/strong><\/p>\n

        Multiple System Atrophy (MSA)- Pipeline Insights, 2021<\/span><\/strong><\/p>\n

        “<\/span>Multiple System Atrophy (MSA) Pipeline Insight, 2021<\/span>” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the  Multiple System Atrophy (MSA) market. A detailed picture of the  Multiple System Atrophy (MSA) pipeline landscape is provided, which includes the disease overview and  Multiple System Atrophy (MSA) treatment guidelines.<\/span><\/p>\n

        Multiple System Atrophy (MSA)- Epidemiology Forecast to 2030<\/span><\/strong><\/p>\n

        DelveInsight’s ‘Multiple System Atrophy (MSA) – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Multiple System Atrophy (MSA) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n

        Media Contact<\/span>
        Company Name:<\/strong>         DelveInsight Business Research LLP<\/a>
        Contact Person:<\/strong> Kritika Rehani
        Email:<\/strong>         Send Email<\/a>
        Phone:<\/strong> 9193216187
        Address:<\/strong>304 S. Jones Blvd #2432
        City:<\/strong> Las Vegas
        State:<\/strong> Nevada
        Country:<\/strong> United States
        Website:<\/strong>         https:\/\/www.delveinsight.com\/<\/a><\/p>\n

        <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

        Delveisight Business Research LLP DelveInsight\u2019s \u2018Multiple System Atrophy (MSA)-Market Insights, Epidemiology, and Market Forecast\u20132030\u2019 report deliver an in-depth understanding of the MSA, historical and forecasted epidemiology as well as the MSA market trends in the United States, EU5 (Germany, France, … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-543918","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/543918","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=543918"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/543918\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=543918"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=543918"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=543918"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}